232 related articles for article (PubMed ID: 37773066)
1. Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants.
Pal A; Gonzalez-Malerva L; Eaton S; Xu C; Zhang Y; Grief D; Sakala L; Nwekwo L; Zeng J; Christensen G; Gupta C; Streitwieser E; Singharoy A; Park JG; LaBaer J
NPJ Breast Cancer; 2023 Sep; 9(1):78. PubMed ID: 37773066
[TBL] [Abstract][Full Text] [Related]
2. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
3. The P72R Polymorphism in R248Q/W p53 Mutants Modifies the Mutant Effect on Epithelial to Mesenchymal Transition Phenotype and Cell Invasion via CXCL1 Expression.
De Souza C; Madden JA; Minn D; Kumar VE; Montoya DJ; Nambiar R; Zhu Z; Xiao WW; Tahmassebi N; Kathi H; Nelson N; Karnezis AN; Chien J
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126568
[TBL] [Abstract][Full Text] [Related]
4. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
McCann JJ; Vasilevskaya IA; McNair C; Gallagher P; Neupane NP; de Leeuw R; Shafi AA; Dylgjeri E; Mandigo AC; Schiewer MJ; Knudsen KE
Oncogene; 2022 Jan; 41(3):444-458. PubMed ID: 34773073
[TBL] [Abstract][Full Text] [Related]
6. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
8. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
9. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.
Odell AF; Odell LR; Askham JM; Alogheli H; Ponnambalam S; Hollstein M
J Biol Chem; 2013 Jun; 288(23):16704-16714. PubMed ID: 23612969
[TBL] [Abstract][Full Text] [Related]
10. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
11. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
12. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 gain of function induces HER2 over-expression in cancer cells.
Román-Rosales AA; García-Villa E; Herrera LA; Gariglio P; Díaz-Chávez J
BMC Cancer; 2018 Jul; 18(1):709. PubMed ID: 29970031
[TBL] [Abstract][Full Text] [Related]
14. Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity.
Thompson LR; Oliveira TG; Hermann ER; Chowanadisai W; Clarke SL; Montgomery MR
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942535
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
Balasundaram A; Doss CGP
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
[TBL] [Abstract][Full Text] [Related]
17. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
18. Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA.
Lepre MG; Omar SI; Grasso G; Morbiducci U; Deriu MA; Tuszynski JA
Molecules; 2017 Aug; 22(8):. PubMed ID: 28813011
[TBL] [Abstract][Full Text] [Related]
19. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
20. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
